Abstract Microglia are considered to be potential antigen-presenting cells and have the ability to present antigen under pathological conditions. Nevertheless, whether and how microglia are involved in immune regulation are largely unknown. Here, we investigated the suppressive activity of microglia during experimental autoimmune encephalomyelitis (EAE) induced by myelin oligodendrocyte glycoprotein, with the goal of understanding their role in regulating the T cell reaction. Using flow cytometric analysis, we found that microglia were characterized by increased cell number and up-regulated programmed death ligand-1 (PD-L1) at the peak phase of EAE. Meanwhile, both the CD4
Introduction
Experimental autoimmune encephalomyelitis (EAE), characterized by primary demyelination of axonal tracts in the central nervous system (CNS), is a well-known experimental model for the human inflammatory demyelinating disease, multiple sclerosis (MS). Mice with EAE usually experience an acute paralytic episode followed by partial recovery [1] . While both Th1 and Th17 cells are involved in the pathogenesis of EAE [2] , the contributions of these two T cell subsets differ. Th1 cells induce ''classic'' paralytic EAE characterized by monocyte-rich CNS infiltrates and strong pro-inflammatory cytokine responses in the CNS, whereas Th17 cells mediate ''atypical'' ataxic EAE with a relatively mild course in * 50% of mice via an IL-12-independent pathway [3] . Th1 cells, rather than Th17 cells, are highly pathogenic, can lyse autoantigen-presenting astrocytes and fibroblasts, and are required to facilitate the entry of Th17 cells into CNS lesions during EAE [4] . Th1 cells may play a more important role in the pathogenesis of EAE than Th17 cells. Importantly, previous reports have shown that spontaneous remission is, in part, attributable to the clearance of inflammatory Th1 cells from the CNS [5, 6] existence of negative regulation of Th1 cells in EAE. However, the mechanisms underlying the suppression of Th1 cells during EAE remain poorly understood. Microglia, the resident macrophages of the CNS, are exquisitely sensitive to brain injury and disease, and play an important role in the maintenance of CNS homeostasis [7] . Increasing evidence has shown that microglia are involved in the regulation of EAE, as modification of microglial activation affects the progression of EAE [8] [9] [10] [11] . Microglia not only affect neurons by secreting neurotoxic [12, 13] or neuroprotective molecules [14, 15] , but they are also thought to be the principal antigen-presenting cells (APCs) in the CNS and the central player in the pathophysiology of MS [16] , considering its high expression of MHC-II and co-stimulatory molecules. This suggests that microglia regulate the T cell-mediated response that occurs in the CNS. This hypothesis is supported by the finding that IFN-c-stimulated CD11b
? microglia inhibit the differentiation of Th1 cells in vitro, suggesting potential suppressive activity [17] . However, the microglia used in this study were sorted from IFN-cstimulated cultures of cerebral cortical glia from neonatal mice, and differed from those purified from the CNS of EAE mice. So, whether and how microglia modulate the progression of EAE via suppressing Th1 cells need further investigation.
Given the ability of microglia to present antigen to CD4
? T cells [18] , co-stimulatory molecules expressed on microglia may affect T-cell differentiation and function. Previous studies have shown that IFN-c-stimulated microglia express programmed death ligand-1 (PD-L1), an inhibitory co-stimulatory molecule [19] . The receptor of PD-L1, PD1, is known to be expressed by T cells. Therefore, how PD-L1-expressing APCs regulate PD1
? T cells via cell-cell contact has attracted much attention. However, since inflammation and infection would upregulate PD1 in microglia, which express PD-L1 as well [20] [21] [22] , the effect of PD-L1-PD1 interaction on microglia is also a matter of interest.
Moreover, previous reports have indicated that macrophages with higher PD-L1 expression produced more NO [23] . As the resident macrophages of the brain, microglia also upregulate PD-L1 and NO upon LPS/IFN-c stimulation [24] . This sparked our interest in the relationship between PD-L1 and NO in microglia during EAE. That NO strongly affects Th1 cell differentiation has been demonstrated in NOS2/iNOS KO mice [25] [26] [27] , so there may be an alternative pathway in microglia that depends on PD-L1-PD1 interaction, and is responsible for modulation of the CD4
? T cell response via NO production. We therefore set out to investigate these possibilities.
Materials and Methods

Animals
C57BL/6 (H-2 K b ) mice were purchased from Vital River (Beijing, China). OVA 323-339 peptide-specific TCR transgenic mice (OT-II mice) were obtained from the Jackson Laboratory (Bar Harbor, ME). All mice were housed and cared for according to protocols approved by the Animal Care and Use Committee of Taishan Medical University.
Reagents and Antibodies
Fluorescein-conjugated antibodies specific for the mouse antigens CD4 (GK1.5), CD11b (M1/70), CD11c (N418), CD45 (30-F11), IA/IE (MKS4), CD86 (GL1), PD-L1 (M1H5), PD-L2 (TY25), B7-H2 (MIH12), PD1 (J43), IFNc (554412), and iNOS (CXNFT) were from eBioscience (San Diego, CA) or BD Pharmingen (San Diego, CA). Magnetic bead-conjugated anti-mouse antibodies (mAbs) to B220 (RA3-6B2) and CD4 (L3T4) were from Miltenyi Biotec (Bergisch Gladbach, Germany). Purified anti-mouse CD16-CD32 (2.4G2) was from BD Pharmingen and purified anti-CD3 (145-2C11), anti-CD28 (37.51), and anti-PD-L1 (M1H5) were from eBioscience.
RPMI-1640 medium (PAA Laboratories, Linz, Austria) was supplemented with 10% (v/v) FBS (PAA Laboratories), 2 mmol/L L-glutamine (Gibco Life Technologies, Grand Island, NY), 0.01 mol/L HEPES pH 7.2 (Gibco), 1 mmol/L sodium pyruvate (Gibco), 200 U/mL penicillinstreptomycin (Gibco) and 0.055 mmol/L b-mercaptoethanol (Gibco). Complete Freund's adjuvant (CFA), pertussis toxin (PTx), L-N x -nitroarginine methyl ester (L-NAME), 4 0 ,6-diamidino-2-phenylindole (DAPI), paraformaldehyde (PFA), collagenase II, Dnase I, polyvinylpyrrolidone, Triton X-100, bovine serum albumin, and normal goat serum were from Sigma-Aldrich (St Louis, MO). Percoll (GE Healthcare, Uppsala, Sweden), Mycobacterium tuberculosis H37Ra (Difco Laboratories, Detroit, MI), Cytofix/Cytoperm kit (BD Pharmingen, San Diego, CA), Tissue-Tek OCT (optimal cutting temperature) compound (Sakura Finetek, Torrance, CA), and collagenase IV (Gibco Life Technologies) were also used.
Induction and Assessment of EAE
Using the method described by Stromnes [1] , mice were injected subcutaneously with 300 lg MOG peptide (MEVGWYRSPFSRVVHLYRNGK) in CFA containing 4 mg/mL M. tuberculosis H37Ra at four sites on the back. PTx (400 ng) was given intraperitoneally on days 0 and 2 post-immunization. Clinical EAE status was scored as follows [1] : 0, no clinical symptoms; 0.5, partially limp tail; 1, completely limp tail; 1.5, limp tail and hindlimb weakness; 2, partial hindlimb paralysis; 2.5, complete unilateral hindlimb paralysis; 3, complete bilateral hindlimb paralysis; 3.5, complete bilateral hindlimb paralysis and partial forelimb paralysis; 4, paralysis of forelimbs and hindlimbs; and 5, death.
Isolation of CNS Mononuclear Cells
Mononuclear cells were isolated from the CNS as previously described [28] with modifications. Briefly, mice were perfused through the left ventricle with cold 0.01 mol/L PBS. The brain and spinal cord were cut into pieces and digested with collagenase II (2 lg/mL) and Dnase I (1 mg/ mL) at 37°C for 1 h. Cells were isolated by passing the tissue through a cell strainer (70 lm), followed by Percoll gradient (70%/40%) centrifugation. Mononuclear cells were removed from the interface, washed, and re-suspended in culture medium for further analysis.
Isolation of Splenocytes
The spleen was digested for 30 min at 37°C in collagenase IV (1 mg/mL) and the cell suspension was filtered through a cell strainer (70 lm). Red blood cells were lysed with ACK lysing buffer (Gibco Life Technologies).
Flow Cytometry
For cell surface staining, after blocking with 2.4G2, cells were stained with anti-CD45-eFlur650, anti-CD11b-FITC, anti-IA/IE-PE-cy7, anti-CD86-PE, anti-PD-L1-PE, anti-PD-L2-PE, or anti-B7-H2-PE mAbs to analyze microglia or with mouse anti-CD4-FITC or anti-PD1-PE-cy7 antibody to analyze PD1 expression on CD4
? T cells. For iNOS staining, after blocking with anti-FcR mAb (2.4G2), cells were stained with anti-CD45-eFlur650, anti-CD11b-PE, or CD4-percp-cy5.5, fixed and permeabilized with the Cytofix/Cytoperm kit, and then stained with anti-iNOS-FITC. For intracellular cytokine staining, after blocking with anti-FcR mAb (2.4G2) and staining with anti-CD4-FITC, cells were fixed and permeabilized with the Cytofix/ Cytoperm kit and then stained with anti-IFN-c-PE. To assess T-cell proliferation, cells were blocked with antiFcR mAb (2.4G2) and stained with anti-CD4-FITC mAb. Then PBS was added to each well to a final volume of 300 lL. Finally, cells were collected at high speed for 50 s, and the CD4
? T cells were counted on a BD FACS Aria II Flow Cytometer as described elsewhere [29] .
For cell sorting, CNS mononuclear cells were isolated from mice at the peak of EAE. The Fc receptor was blocked with anti-mouse FcR (2.4G2), followed by staining with anti-CD45-eFlur650 and CD11b-PE, and CD45 low-
CD11b
? cells were recognized as microglia [30, 31] . CD4
? T cells were purified from the spleens of 8-week-old OT-II mice via positive selection using CD4-coated microbeads. The positive cells were labeled with anti-CD4-FITC and anti-CD62L-PE mAb. The CD4
? CD62L high cells were sorted as naive T cells.
For T cell-proliferation assays, naive T cells were labeled with Cell Proliferation Dye eFluor Ò 450 (eBioscience). To isolate splenic dendritic cells (spDCs), B220 -splenocytes were collected by negative selection with B220-coated magnetic microbeads. The negative cells were further labeled with anti-CD11c-APC and anti-IA/IE-PEcy7 mAb, and CD11c
hi Ia hi cells were recognized as DCs. Finally, all cells were sorted on the BD FACS Aria II Flow Cytometer.
Proliferation and Inhibition Assays
In a total volume of 200 lL in 96-well round-bottom plates, 1 9 10 5 OT-II naive CD4 ? T cells labeled with eFluor Ò 450 were co-incubated with microglia (4 9 10 4 cells/well), splenic DCs (2 9 10 4 /well), or microglia/ splenic DCs in the presence of OVA 323-339 (ISQAV-HAAHAEINEAGR, 10 lg/mL) at 37°C under 5% CO 2 for 72 h. Then viable cell numbers and CD4
? T cell differentiation were counted on the FACS Aria II Flow Cytometer. To analyze the action of microglia on CD4
? T cell differentiation, the co-cultured cells were further restimulated with anti-CD3 (10 lg/mL) and anti-CD28 (2 lg/mL) mAbs for 5 h in the presence of GolgiStop (BD Pharmingen). The percentage of IFNc ? CD4 ? T cells was analyzed on the FACSAria II. In some experiments, anti-PD-L1 mAb (10 lg/mL) or an iNOS inhibitor (L-NAME, 0.5 mmol/L) was added at the beginning of culture.
Immunohistofluorescent Staining
Mice were perfused through the left ventricle with 0.01 mol/L PBS followed by 0.1 mol/L PBS containing 4% PFA. Spinal cord tissue was collected, post-fixed in 0.1 mol/L PBS containing 4% PFA overnight at room temperature, and embedded in OCT. Sections (20 lm) were processed and stored at -20°C in anti-freeze solution containing 0.05 mol/L PBS, 30% sucrose, 1% polyvinylpyrrolidone, and 30% ethylene glycol until use.
Double labeling for CD4 and PD1 was carried out in a one-step procedure. Selected sections from anti-freeze solution were blocked with blocking buffer (0.4% Triton X-100, 1% FBS, and anti-mouse FcR (2.4G2) (1:100) in 0.01 mol/L PBS) for 60 min. After incubation with anti-CD4-FITC and anti-PD1-PE-Cy7 mAbs at room temperature for 2 h, the sections were incubated with DAPI for 5 min, then they were mounted and coverslipped. Images were captured using spinning-disk confocal microscopy (Leica SD AF, Wetzla, Germany).
Systemic Administration of iNOS Inhibitor During EAE
L-NAME dissolved in 0.2 mL sterile saline (125 mg/kg) or saline was injected intraperitoneally into mice with EAE (twice per day) from day 14 until day 22 post-immunization. Animals were sacrificed the day after the last injection and mononuclear cells from the CNS were prepared to analyze the percentage of IFN-c ? CD4 ? T cells.
Quantitative PCR Analysis of iNOS Expression
RNA was extracted from microglia and CD4 ? T cells sorted from the CNS at the peak phase of EAE using an RNeasy Mini Kit (Qiagen) according to the manufacturers' recommendations. Aliquots of each RNA sample (1 lg) were reverse-transcribed to produce cDNA using a QuantiTect Reverse Transcription Kit (Qiagen). Quantitative realtime PCR (qPCR) was performed with a Rotor-Gene SYBR Green PCR Kit (Qiagen) on a Rotor-Gene Q cycler (Qiagen). Samples were analyzed in triplicate and experiments were performed at least three times. The absolute number of gene copies was normalized to GAPDH and standardized using a sample standard curve. iNOS primer sequences were as follows: sense strand: 5 0 GTT CTC AGC CCA ACA ATA CAA GA 3 0 , anti-sense strand: 5 0 GTG GAC GGG TCG ATG TCA C 3 0 .
Measurement of NO Production
The nitrite concentration in culture supernatants was measured colorimetrically using the Griess assay. Cell-free supernatant (100 lL) was added to a microtiter plate containing 100 lL 1% sulfanilamide and 0.1% naphthylethylenediamine in 2.5% H 3 PO 4 . The absorbance value was measured at 550 nm after 10 min.
Statistical Analysis
All experiments were designed and performed in accordance with the ARRIVE guidelines. Data are expressed as mean ± SD and were analyzed with two-tailed Student's t test using the GraphPad Prism 5 software package. P \ 0.05 was considered statistically significant.
Results
Microglial Numbers Increase and PD-L1 Expression is Upregulated During EAE
EAE was induced in C57BL/6 mice by subcutaneous injection of MOG ; it was characterized by monophasic paralysis followed by spontaneous partial remission [1] . Based on the clinical score and the number of days postimmunization [32, 33] , EAE was classified into five progressive stages: the pre-onset phase (score 0, 4-6 days post-injection, dpi); the onset phase (score 0.5-1, 9-11 dpi); the increasing phase (score 1-2.5, 12-16 dpi); the peak phase (score 2.5-3.5, 17-23 dpi); and the remission phase (score 1-0.5, 30-35 dpi). Naive mice were set as controls (Fig. 1A) .
To investigate whether microglia are involved in MOGinduced neuroinflammation, we first evaluated the dynamic changes in the numbers of microglia during EAE. The percentage of microglia (CD45 low CD11b ? ) [30, 31] among leukocytes gradually decreased until the peak phase, followed by a rebound at remission (Fig. 1B) . This change was contrary to that of the cell count, which could be explained by the remarkable infiltration of leukocytes from the beginning and their subsequent retraction at the remission of EAE.
The changes in the numbers of microglia indicated their involvement in the pathogenesis of EAE, and were consistent with previous reports that microglia become activated and participate in EAE [9] . To gain further insights into the function of microglia in vivo, flow cytometry was used to assess the expression of antigen presentationrelated molecules on microglia following MOG-immunization. Compared with naïve controls, microglia from EAE mice at different stages displayed significant dynamic changes in the expression of MHC class II (Fig. 1C) , CD86 (Fig. 1D) , and PD-L1 (Fig. 1E) . However, PD-L2 and B7-H2 expression was relatively stable (data not shown).
In detail, the expression of MHC II and CD86 was upregulated from the pre-onset phase and reached a maximum at the increasing and onset phases, suggesting that microglia became activated and participated in antigenpresentation. We also found increased expression of PD-L1 on microglia from EAE mice, beginning from the pre-onset phase until the peak phase followed by a decrease thereafter. The start and the peak of PD-L1 upregulation were delayed compared with MHC II and CD86. This discrepancy suggested a functional change in microglia with the development of EAE, considering the PD-L1-mediated suppression of EAE severity and progression demonstrated in PD-L1 -/-mice or mice with PD-L1 blockade [34] [35] [36] . Therefore, we further explored the regulatory effect of PD-L1 on microglia.
Infiltrating CD4
1 T Cells in the CNS Upregulate PD1 Expression During EAE Flow cytometry showed that the CD4
? T cells infiltrating the CNS displayed gradual upregulation of PD1, reaching the highest level at the peak phase of EAE followed by a decrease at remission (Fig. 2A) . To further confirm the PD1 expression on CD4
? T cells, immunohistofluorescence showed that, at the peak phase of EAE, CD4
? PD1
?
T cells occurred mainly in the anterior median fissure, the posterior median sulcus, and the lateral funiculus of the white matter in the spinal cord, while neither CD4 ? T cells nor PD1 expression was found in the CNS of naive mice (Fig. 2B) .
To explore the relationship between PD-L1 expression and the CD4
? T cell response, dynamic changes in the Th1 cells infiltrating the brain and spinal cord during EAE were assessed. Mononuclear cells prepared from the CNS were stimulated with anti-CD3 and anti-CD28 mAbs for 5 h. Intracellular cytokine staining was performed, and the cells were analyzed by flow cytometry. The percentage of IFNc ? CD4
? T cells (referred to as Th1 cells) in the CNS gradually increased and reached a maximum after the increasing phase, followed by a decrease thereafter (Fig. 2C) . Of interest, the decline of Th1 cells was accompanied by a remarkable increase in PD-L1 expression on microglia (Fig. 1E) , suggesting that Th1 cell reduction might be associated with microglial PD-L1.
Microglia Sorted from EAE Mice Suppress CD4 1 T Cell Proliferation and Th1 Differentiation in a PD-L1-Dependent Manner
To investigate whether microglia negatively regulate CD4 ? T cells, proliferation assays were performed by 72-h coculture of OT-II CD4
? T cells and OVA 323-339 -loaded splenic DCs (spDCs) in the presence or absence of microglia sorted from mice at the peak phase of EAE. The OVA 323-339 -pulsed spDCs but not microglia stimulated the proliferation of CD4
? T cells (Fig. 3A) . Interestingly, the spDC-initiated CD4
? T cell proliferation was significantly inhibited when microglia were added. By assessing the intracellular IFN-c of CD4
? T cells in the co-culture, we further found a significant inhibition of IFN-c ? CD4 ? Th1 cell differentiation by microglia sorted from EAE mice (Fig. 3B) . Therefore, we demonstrated ex vivo that microglia from mice at the peak phase of EAE suppress CD4
? T cell proliferation and Th1 cell differentiation. Considering the simultaneous upregulation of PD-L1 on microglia (Fig. 1E) and PD1 on CD4
? T cells ( Fig. 2A ) in the course of EAE, we speculated that microglia might exhibit inhibitory effects through the PD-L1/PD1 pathway. Thus, we assessed the proliferation and differentiation of CD4 ? T cells using co-culture systems in the presence of anti-PD-L1 mAb or isotype control. After administration of PD-L1-blocking mAb, we found that both the CD4
? T cell count and the percentage of Th1 cells were significantly higher in the microglia/CD4
? T group and the microglia/ spDC/CD4
? T group than that without PD-L1 blockade, suggesting that microglia inhibit CD4
? T cells in a PD-L1-dependent manner (Fig. 3C, D) .
Microglia-Mediated Suppression of Th1 Cells Depends on NO
From the data above, we concluded that PD-L1-expressing microglia regulate PD1-expressing Th1 cells via cell-cell contact, which has been demonstrated in other disease models [37] [38] [39] . However, it remained unclear whether other alternative pathways exist in microglia that depend on PD-L1-PD1 interaction and are responsible for modulation of the CD4 ? T cell response. We supposed that microglia secrete certain soluble factors to regulate the CD4 ? T cell response. Previous reports have indicated that LPS/IFN-c stimulation promotes microglia to produce NO [24] , an important molecule that strongly affects Th1 cell differentiation [25, 26, 40] and EAE development [41, 42] . This sparked our interest in whether microglia activated during EAE exhibit suppressive activity via the production of NO.
qPCR and flow cytometry revealed much higher expression of iNOS on microglia from mice at the peak phase of EAE than that from naive mice (Fig. 4A, B) . Further, the concentration of NO in the culture supernatant from the microglia/CD4
? T group or the microglia/spDC/ CD4
? T group was significantly higher than that from the spDC/T group (Fig. 4C) , suggesting the involvement of NO in microglia-mediated immunoregulation. Confirming the effect of NO on the suppression of CD4
? T cells, addition of the iNOS inhibitor L-NAME into the co-culture 
CD4
? T cells (Th1) was assessed from CD4
? T cells (n = 5). *P \ 0.05 compared with control. Data represent the mean ± SD of three separate experiments. system or injection of L-NAME into the peritoneal cavity of mice from 14 to 22 dpi significantly restored the suppressed CD4
? T cell proliferation and Th1 differentiation mediated by microglia ex vivo (Fig. 4D) . Moreover, more IFN-c ? CD4 ? Th1 cells were observed in the CNS of EAE mice once NO production had been blocked (Fig. 4E) . These data demonstrated that NO contributes to Th1 cell suppression in EAE.
PD-L1 Regulates NO Production by Microglia
To determine whether CD4
? T cells also act as producers of NO, we simultaneously sorted microglia and CD4
? T cells from mice at the peak phase of EAE and analyzed iNOS expression by qPCR and flow cytometry. iNOS expression was detected in microglia, but not in CD4
? T cells (Fig. 5A,  B) . Similar results were also obtained in cells from the coculture system (data not shown). To further reveal the relationship between PD-L1 and NO expressed on microglia, blocking experiments were performed in the co-culture system. We found that blocking PD-L1 led to lower levels of NO in the microglia/OT II T cell co-culture with or without spDCs (Fig. 5C ), indicating the regulation of NO by PD-L1 in microglia. Flow cytometry showed that microglia activated during EAE upregulated PD1 expression in a manner similar to PD-L1 (Fig. 5D) , consistent with previous reports that inflammation and infection upregulate both PD-L1 and PD1 in microglia [20] [21] [22] . Therefore, we speculated that activated microglia not only interact with PD1-expressing CD4
? T cells, but also crosstalk with nearby microglia via PD-L1-PD1 interaction, thus promoting NO production by microglia.
Discussion
As an animal model for T cell-mediated autoimmune disease, EAE has pathological hallmarks similar to MS, including white matter demyelination, inflammation, axonal damage, and blood-brain barrier disruption. (10 lg/mL) and anti-CD28 mAbs (2 lg/mL) into the co-culture system and incubation for 5 h, the percentage of IFNc ?
CD4
? T cells was analyzed by flow cytometry (n = 3). C-D In blocking experiments, anti-PD-L1 mAb (10 lg/mL) or matched isotype control was added into different co-culture systems (n = 3). CD4
? T cell proliferation (C) and Th1 cell differentiation (D) were analyzed by flow cytometry. Data are presented as mean ± SD (*P \ 0.05). The results shown above are representative of at least three independent experiments.
Interestingly, MOG-induced EAE is characterized by monophasic paralysis, which implies the involvement of negative immunoregulation. Previous studies have shown that peripheral CD4
? Foxp3 ? Treg cells participate in the control of neuroinflammation [43, 44] . However, little is known about the contribution of CNS-resident cells to the control of EAE. In the present study, we described the dynamic changes of microglia and Th1 cells in EAE mice in vivo, and found that microglia inhibited CD4
? T cell proliferation and Th1 cell differentiation ex vivo. Further, Fig. 4 Th1 cell differentiation was suppressed by microglia sorted from EAE mice via NO. A Microglia sorted from mice at the peak phase of EAE and naive mice were assessed for the expression of iNOS mRNA by qPCR (n = 4). B Mononuclear cells in the CNS from EAE mice at the peak phase and naive mice were purified and stained with anti-CD45, anti-CD11b, and anti-iNOS mAbs for flow cytometric analysis. Microglia were analyzed for iNOS expression (n = 5). C Supernatant of the co-culture that included CNS-sorted microglia form EAE mice at the peak phase was prepared to analyze NO by Griess assay; values are expressed as the percentage of nitrite relative to T cells alone (n = 3). D Using the same co-culture system, an iNOS inhibitor (L-NAME, 0.5 mmol/L) was used to block NO production, and then CD4
? T cell proliferation (left) as well as Th1 cell differentiation (right) were assessed (n = 3). E L-NAME (125 mg/kg) or saline was injected intraperitoneally into mice (n = 8) twice a day from day 14 to day 22 after immunization. The day after the last injection, mononuclear cells from the CNS were prepared and stimulated by anti-CD3 (10 lg/mL) and anti-CD28 mAbs (2 lg/mL). Five hours later, cells were stained with anti-CD4 and anti-IFN-c mAbs for flow cytometric analysis. *P \ 0.05. Data are presented as mean ± SD of triplicate samples.
PD-L1 expressed on microglia regulated Th1 cell differentiation via NO, suggesting a role of microglia in regulating autoimmune neuroinflammation.
Microglia, originating from the yolk sac [45] , represent *5-20% of total glial cells in rodents. As the CNS-resident immune cells, microglia play an important role in both physiological and pathological conditions. Although the physiological functions of microglia are only partially understood, their key role in certain neurodegenerative disorders is well established [9, 13, 46] . Furthermore, increasing evidence supports the concept that microglia function as a bridge between the CNS and immune systems in autoimmune neuroinflammation, such as in MS and EAE [18, [46] [47] [48] . Despite the infiltration of peripheral leukocytes into the CNS, the resident microglia become activated and are required for autoimmune responses. It is noteworthy that modulation of microglial activation can change the outcome of EAE [8] [9] [10] [11] . Altered production of neurotoxic or neuroprotective molecules by microglia may explain this phenomenon. Moreover, the regulation of CD4
? T cells by microglia should also be considered.
As an APC, the intrinsic function of microglia in adaptive immunity is their capability of antigen presentation. It is now clear that microglia scarcely present antigens to stimulate T cells based on the negligible expression of MHC class II molecules in the healthy CNS [11, 18] . During inflammation, there is marked upregulation of MHC class II and co-stimulatory molecules on microglia, indicating an enhanced ability to trigger CD4
? T cells. Nevertheless, the expression of antigen presentation-associated molecules on microglia declines when EAE recovery begins, suggesting less efficient APCs at this time [16] . Our ex vivo results indicated that microglia at the peak phase of EAE have a limited stimulatory ability compared with spDCs, consistent with previous reports [37, 49] . Furthermore, microglia sorted from EAE mice inhibited spDC-triggered antigen-specific CD4
? T cell proliferation and Th1 cell differentiation ex vivo. These results suggested that microglia negatively regulate the CD4
? T cell response in EAE.
To further investigate the mechanism of microgliamediated immunoregulation, we investigated changes in ? T cells were sorted from the CNS of mice at the peak phase of EAE and assessed for the expression of iNOS mRNA by qPCR. ND indicates no detection (n = 4). C To determine the effect of PD-L1 on NO production, anti-PD-L1 mAb (10 lg/mL) or isotype antibody was added into co-culture systems that included CNS-sorted microglia from mice at the peak phase of EAE. Culture supernatant was prepared for NO analysis by Griess assay; values are expressed as the percentage of nitrite relative to T cells alone (n = 3). D CNS mononuclear cells were prepared from mice at different phases of EAE (n = 5). CD45 low CD11b ? microglia were gated to evaluate the expressions of PD1 by flow cytometry *P \ 0.05. Data are presented as mean ± SD of triplicate samples.
the surface expression of molecules on microglia during EAE. PD-L1, a member of the co-stimulatory molecule family, was upregulated on microglia from the increasing phase of EAE in this study, similar to a previous report [19] . Furthermore, PD-L1 deficiency or PD-L1 blockade leads to aggravated symptoms of EAE, demonstrating the important regulatory role of PD-L1 in neuroinflammation [35, 36, 50] . The receptor for PD-L1, PD1 was also upregulated on CNS-infiltrating CD4
? T cells, suggesting an interaction between microglia and CD4
? T cells. We thus designed suppression-associated experiments as in a previous report [51] , and found that neutralization of PD-L1 on microglia partially restored the CD4
? T cell proliferation and Th1 cell differentiation. This finding indicated that microglia suppresses Th1 cell differentiation in a PD-L1-dependent manner, which is consistent with the previous report that PD-L1 blockade impairs the stimulation of activated PD1
? T cells by microglia ex vivo [37] . The PD-L1/PD1 pathway has been shown to deliver inhibitory signals that regulate both central and peripheral immune tolerance. In the thymus, signals through PD1 regulate the signaling threshold during positive selection and participate in negative selection [52, 53] . In peripheral T-cell tolerance, the PD-L1/PD1 pathway regulates the T cell response in several ways. First, it limits the initial phase of activation and expansion of naive self-reactive T cells, and/or inhibits their differentiation into effector T cells. Second, the PD-L1/PD1 pathway can negatively regulate the reactivation, expansion, and/or functions of effector T cells [54, 55] . Notably, this pathway controls the development, maintenance, and function of induced Treg cells. In EAE, how do microglia suppress CD4
? T cell proliferation and Th1 cell differentiation through the PD-L1/PD1 pathway? Apart from direct suppression of Th1 cells via cell-cell contact, we speculate that microglia exert suppression by the PD-L1-dependent production of certain molecules.
Previous reports have shown that PD-L1 expression is associated with the ability of macrophages to produce NO [23] . As the resident macrophages in the brain, microglia also upregulate PD-L1 and NO upon LPS/IFN-c stimulation [24] . So, it is worthwhile to investigate whether NO acts as an effector molecule in microglia-mediated suppression. NO has long been considered as an important proinflammatory cytotoxic mediator to defend against various pathogens by inactivating and destroying infectious agents [56] . Further studies in NOS2/iNOS KO mice revealed that NO suppresses Th1 cells [25] [26] [27] . The underlying mechanisms are considered to be associated with the modulation of APC function and maturation. For example, NO inhibits IL-12p70 production by IFN-c/LPS-treated mouse bone marrow-derived DCs [57] and LPS-treated human monocyte-derived DCs [58] ; and autocrine NO affects the maturation of inflammatory DCs and the DC programming of T cells [59] . Our data showed that blocking NO resulted in partial recovery of the CD4
? T cell proliferation and Th1 cell differentiation suppressed by microglia, suggesting the involvement of NO in microglia-mediated suppression. By intraperitoneal administration of an iNOS inhibitor, we also found increased Th1 cells in the CNS of the EAE model, which was consistent with the results from the co-culture system. However, how PD-L1 affects NO production by microglia is not well known and needs further study.
As NO is known to be involved in the microglia-mediated suppression of CD4
? T cells, it is of interest to evaluate the relationship between PD-L1 and NO. Our results showed that neutralization of PD-L1 led to weak production of NO by microglia but not by CD4
? T cells, suggesting the regulation of NO synthesis by PD-L1 signaling. Given the upregulation of PD1 on activated microglia, we suggest that the crosstalk among activated microglia via PD-L1-PD1 interaction leads to their production of NO, which subsequently suppresses CD4
? T cells. Our next project is to study the key signal pathways involved in NO-mediated Th1 cell suppression.
Taken together, our findings indicate that microglia from EAE mice suppress CD4
? T cell proliferation and Th1 cell differentiation. The inhibitory mechanisms of microglia are associated with the PD-L1/PD1 pathway which promotes NO production. These results deepen understanding of the role of microglia in EAE pathogenesis, and provide a theoretical and experimental basis for better treatment of MS patients in the future. However, we still cannot exclude the possibility that T cells themselves might interact with nearby T cells through the PD-L1/PD1 pathway to regulate the CD4
? T cell response, as PD-L1 is constitutively expressed on CD4
? T cells and is further upregulated upon their activation [60] . To test this hypothesis, mice characterized by CD4
? T cell-specific knockout of PD-L1 by the Cre-Loxp hybrid technique are required. Moreover, we also found dynamic changes of Th17 and Treg cells in the course of EAE (data not shown), but whether microglia affect these cells needs further investigation.
